Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Processa Pharmaceuticals Inc

PCSA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$1.86

▲ +5.68%

Market Cap $5.20M · Vol 1.44K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.20M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

60.92

Momentum

Beta

1.27

vs Market

52W High

$10.80

83.71% below

52W Low

$1.12

57.14% above

Volume

1.44K

Avg 18.41K

P/B

1.33

Price-to-book

ROE

N/A

Return on equity

Free Float

85.18%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Processa Pharmaceuticals Inc (PCSA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PCSA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.71%

-2.11%

-26.77%

-39.41%

YTD

-35.42%

-73.26%

-98.84%

-99.95%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-13,563,830.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-245.66% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.33
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	2.79M

Technical Indicators

50-Day SMA	$1.90
200-Day SMA	$2.41
RSI (14)	60.92
Beta	1.27
52-Week High	$10.80
52-Week Low	$1.12

Volume Today	1.44K
Avg Daily Volume (30D)	18.41K
Relative Volume	0.08x
Volatility (10D)	135.70
Volatility (30D)	107.89
Free Float	85.18%

Analyst Consensus

N/A

Current Price $1.86

Mean Target N/A

52W Low$1.12 52W High$10.80

Current

Target

$1.12 $10.80

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG003MN60F5

ISINUS74275C4033

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.